Lifanda Biotech

Lifanda Biotech is a clinical-stage biotechnology company based in Suzhou, China, specializing in the development of mRNA-based vaccines and therapeutics. The company leverages a proprietary lipid nanoparticle (LNP) delivery platform and an integrated mRNA synthesis technology to design highly stable and potent medical candidates. Its lead program is a next-generation mRNA vaccine for COVID-19, which has progressed through Phase 2 clinical trials. Beyond infectious diseases, Lifanda is expanding its research into oncology and other therapeutic areas where mRNA technology can provide transformative solutions. The company maintains its own GMP-compliant manufacturing facilities to support both clinical development and future commercialization.